Literature DB >> 1701222

[Monoclonal antibodies and mediators--immunologic tumor therapy].

D Baron1.   

Abstract

Immunological tumor therapy includes the use of interferons, interleukins, tumor necrosis factor, and monoclonal antibodies. Clinical tests performed on about 20 types of solid tumors and 10 types of leukemias and lymphomas showed rather limited success. In many cases the side effects are considerable, resulting in the interruption or cessation of therapy. Improvements can be achieved by gene technology. Only the interferons have been approved as official drugs to treat cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701222     DOI: 10.1007/bf01135937

Source DB:  PubMed          Journal:  Naturwissenschaften        ISSN: 0028-1042


  6 in total

Review 1.  [Production and application of monoclonal antibodies].

Authors:  W G Bessler; D Baron
Journal:  Naturwissenschaften       Date:  1988-10

2.  Lymphokines and monokines in the clinic.

Authors:  E Platter; M Gramatzki; M Röllinghoff; J R Kalden
Journal:  Immunol Today       Date:  1986 Jul-Aug

Review 3.  Engineering of antibodies.

Authors:  M Verhoeyen; L Riechmann
Journal:  Bioessays       Date:  1988 Feb-Mar       Impact factor: 4.345

4.  Immunotherapy of metastatic disease.

Authors:  J E Talmadge; P L Black
Journal:  Semin Thromb Hemost       Date:  1988-01       Impact factor: 4.180

Review 5.  Monoclonal antibodies for treating cancer.

Authors:  R O Dillman
Journal:  Ann Intern Med       Date:  1989-10-01       Impact factor: 25.391

6.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.